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Summary: In this large cohort of HIV-infected patients on first-line ART in Zambia, 
individuals who started a tenofovir-containing regimen despite baseline renal 
dysfunction showed comparable mortality and renal function improvement to those 
not on tenofovir. 
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ABSTRACT 
Background.  Although tenofovir (TDF) use has increased as part of first-line 
antiretroviral therapy (ART) across sub-Saharan Africa, renal outcomes among patients 
receiving TDF remain poorly understood. We assessed changes in renal function and 
mortality in patients starting TDF- or non-TDF-containing ART in Lusaka, Zambia. 
Methods. We included patients aged ≥16 years who started ART from 2007 onward, 
with documented baseline weight and serum creatinine. Renal dysfunction was 
categorized as mild (eGFR 60-89 mL/min), moderate (30-59 mL/min) or severe (<30 
mL/min) using the CKD-EPI formula. Differences in eGFR during ART were analyzed 
using linear mixed-effect models, the odds of developing moderate or severe eGFR 
decrease with logistic regression and mortality with competing risk regression. 
Results. We included 62,230 adults, of which 38,716 (62%) initiated a TDF-based 
regimen. The proportion with moderate or severe renal dysfunction at baseline was 
lower in the TDF compared to the non-TDF group (1.9% vs. 4.0%). Among patients with 
no or mild renal dysfunction, those on TDF were more likely to develop moderate 
(adjusted OR: 3.11; 95%CI: 2.52-3.87) or severe eGFR decrease  (adjusted OR: 2.43; 
95%CI: 1.80-3.28), although the incidence of such episodes was low. Among patients 
with moderate or severe renal dysfunction at baseline, renal function improved 
independently of ART regimen and mortality was similar in both treatment groups. 
Conclusions. TDF use did not attenuate renal function recovery or increase mortality in 
patients with renal dysfunction. Further studies are needed to determine the role of 
routine renal function monitoring before and during ART use in Africa. 
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INTRODUCTION 
In 2007, Zambia was one of the first countries in sub-Saharan Africa (SSA) to introduce 
Tenofovir Disoproxil Fumarate (TDF) as a preferred nucleotide reverse transcriptase 
inhibitor (NRTI) of first line antiretroviral therapy (ART) [1, 2]. The advantages of TDF 
include its high potency against HIV and hepatitis B infections, favorable resistance 
profile, good tolerability and safety, and its availability as a co-formulation with other 
antiretroviral agents in once-daily pills [3-5]. However, in industrialized countries, TDF 
has been associated with nephrotoxicity, including proximal tubulopathy and impaired 
glomerular filtration [6-11]. In SSA, a significant number of HIV-infected patients start 
ART with pre-existing kidney dysfunction, due to either HIV-associated nephropathy or 
to other causes such as hypertension or diabetes [12, 13]. Although the incidence of 
TDF-related kidney dysfunction appears to be low in most settings [8-10, 14], the impact 
of TDF on clinical outcomes in patients starting ART with moderate or severe renal 
dysfunction has not been studied previously. In this report, we evaluated changes in 
renal function and mortality in patients starting TDF- or non-TDF-containing ART 
regimens in a large cohort of HIV infected adults in Lusaka, Zambia.   
 
METHODS 
The Zambian National HIV Program 
Care and treatment provided through the Zambian National HIV Program has been 
described previously [15]. Alongside a detailed medical history and physical 
examination, the baseline screening includes CD4 cell count, hemoglobin, serum 
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creatinine, and aminotransferases. The choice of ART depends on laboratory test 
results, age and comorbidities. Before June 2007, stavudine (d4T) or zidovudine (AZT) 
with 3TC plus a non-nucleoside reverse transcriptase inhibitor (NNRTI), either 
nevirapine (NVP) or EFV, were the recommended first-line agents. Thereafter, TDF 
replaced d4T and AZT as the preferred NRTI alongside 3TC for patients with a 
creatinine clearance ≥ 50mL/minute.  However, as creatinine clearance was not 
calculated routinely, TDF was prescribed in patients with a serum creatinine ≤ 120 
µmol/L. For those with impaired renal function, abacavir (ABC) was prescribed instead 
of TDF. Routine clinical follow-up visits were done every 3 to 6 months and TDF was 
substituted with ABC in patients who developed severe renal dysfunction. Deaths are 
ascertained when reported by a family member, clinic staff member, or community 
health worker. Patient medical information is entered into an electronic database for 
clinical care, monitoring and evaluation, and reporting purposes [16]. These 
programmatic data have received local ethical approval for use in the International 
epidemiological Databases to Evaluate AIDS in Southern Africa (IeDEA-SA) network, a 
large regional collaboration of ART programmes [17]. 
 
Inclusion criteria, definitions, and outcomes 
We included patients aged ≥16 years who started ART in the capital city of Lusaka from 
June 2007, when the Zambian government instituted its national policy to incorporate 
TDF into first-line ART [1]. Those without documented serum creatinine and weight at 
baseline were excluded from the analysis cohort. Due to a lag in roll out of national ART 
guidelines, not all the patients enrolled after June 2007 initiated a TDF-containing ART 
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regimen. We categorized first-line regimens as either TDF-containing regimens (TDF + 
XTC [3TC or FTC] + NVP or EFV) or non-TDF-containing regimens (ABC or d4T or AZT 
+ 3TC + NVP or EFV). Although boosted protease inhibitors (bPI) may be incorporated 
into first-line regimens following NNRTI intolerance, they are typically reserved for 
second-line therapy and are almost never prescribed at ART initiation. In addition, 
because the co-administration of TDF with a bPI has been shown to increase the risk of 
nephrotoxicity and impair renal function [18-20], we excluded all patients who were on a 
bPI-based regimen. As ABC was often prescribed to patients with renal dysfunction at 
baseline, including these patients could have introduced some degree of confounding 
by indication. In an effort to minimize this potential effect, we conducted secondary 
analyses that excluded patients on ABC. 
Serum creatinine concentration was measured using the Cobas Integra 400 Plus 
automated chemistry analyzer (Roche Diagnostics, Basel, Switzerland) from 2007-
2008, and the Olympus AU400 analyzer (Beckman Coulter Diagnostics, Brea, 
California, USA) thereafter. Quality control of chemistry analyzers was performed 
according to manufacturer recommendations. We estimated the glomerular filtration rate 
(eGFR) using the CKD- Epidemiology (CKD-EPI) formula [21]. This method is 
considered more accurate than the Cockroft-Gault and Modification of Diet in Renal 
Disease (MDRD) equations for values > 60 mL/min/1.73 m2 and has recently been 
shown to be accurate in HIV-infected populations as well [22]. In sensitivity analyses, 
we repeated the main analyses using the MDRD and the Cockroft-Gault formulas. In 
line with the Kidney Disease Outcomes Quality Initiative (KDOQI) criteria [23, 24], we 
categorized renal function as follows: normal: eGFR ≥90 mL/min/1.73m2, mild eGFR 
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decrease: eGFR 60 - 89 mL/min/1.73m2, moderate eGFR decrease: eGFR 30 - 59 
mL/min/1.73m2) and severe eGFR decrease:  eGFR ≤29 mL/min/1.73m2. Our outcomes 
of interest were: 1) renal function after 6 and 12 months of ART, 2) the proportion of 
patients developing an episode of moderate or severe eGFR decrease while on ART, 
and 3) mortality. 
 
Statistical analyses 
Baseline characteristics of patients initiating TDF- and non-TDF-containing ART were 
compared using Chi-squared and Mann–Whitney tests. We compared the median 
change in eGFR between patients on TDF and those not on TDF after 6 and 12 months 
of ART, according to baseline renal function category. To estimate the difference in 
renal function over time between the two study groups, we used a multivariable mixed-
effects model (eGFR measurements within patients), using a random intercept with 
unstructured covariance correlation structure, stratified by baseline renal dysfunction 
category. The proportion of patients with a normal renal function or mild renal 
dysfunction at baseline who developed an episode of moderate or severe eGFR 
decrease at 6 or 12 months was compared between the TDF and non TDF groups. 
Adjusted estimates were obtained using a multivariable logistic regression model. We 
used a multivariable competing risk sub-distribution model according to Fine and Gray 
to compare mortality between the two groups, measuring time from the initiation of first-
line ART to the outcome of interest [25]. Accounting for loss to follow-up (LTFU), 
defined as not returning to the health care facility for more than six months, as a 
competing risk of death, limits the production of biased results. All multivariable 
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regression analyses were adjusted for age, sex, calendar year, WHO stage, CD4 count, 
and hemoglobin. Anemia was defined as severe (hemoglobin <5.0 mmol/L (<8.0 g/dL)), 
moderate (5.0–<6.2 mmol/L (8.0-<10.0 g/dL) in women and 5.0–<6.8 mmol/L (8.0-<11.0 
g/dL)in men), mild (6.2–<7.4 mmol/L (10.0-<12.0 g/dL) in women and 6.8–<8.1 mmol/L 
(11.0-<13.0 g/dL) in men) or none (≥7.4 mmol/L (≥12.0 g/dL) in women and ≥8.1 
mmol/L (≥13.0 g/dL) in men). All statistical analyses were performed using Stata 
software version 12.1 (College Station, TX). 
  
RESULTS 
Baseline Characteristics 
In this analysis, we included 62,230 HIV-infected adults who initiated ART between 
January 2007 and February 2011. Of these, 38,716 (62%) started a TDF-containing 
first-line regimen (Table 1). Individuals on TDF started ART with a more advanced stage 
of disease and were more likely to receive EFV compared to those not on TDF. Patients 
not on TDF-containing regimens were more likely to be female and to have started ART 
in earlier years. Age and hemoglobin were similar across treatment groups. Overall, 
patients on TDF were slightly more likely to have some degree of baseline renal 
dysfunction compared to individuals not on TDF-containing ART (16.7% vs. 12.4%). 
However, the proportion of patients with moderate or severe renal dysfunction was two 
times higher in the non-TDF compared to the TDF group (4.0% vs. 1.9%). After ART 
initiation 70.4% of patients on TDF and 84.9% of those on non-TDF regimens had at 
least one repeat creatinine measurement available at either 6 or 12 months of ART.  
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Changes in renal function in patients with no or mild eGFR decrease at baseline 
Among patients who started ART with no renal dysfunction, we observed a slight 
decline in renal function both at 6 and 12 months irrespective of ART regimen (-15 
ml/min in the TDF and -17 ml/min in the non-TDF groups). There was no change in 
renal function over time in those with mild eGFR decrease at baseline (Figure 1). In 
adjusted analyses, patients on TDF had a slightly reduced renal function at 6 and 12 
months compared to those on other ART regimens, although differences were small 
(Table 2). The proportion of patients with no or mild baseline renal dysfunction 
developing an incident episode of severe eGFR decrease at 6 or 12 months was higher 
in the TDF group though not statistically significant (0.28% vs. 0.20%; p=0.26 at 6 
months and 0.24% vs. 0.15%, p=0.20 at 12 months). For the outcome defined as 
incident episodes of moderate or severe eGFR decrease, the differences reached 
statistically significance; however the numbers remained low (1.90% in TDF vs. 1.27% 
in non-TDF; p<0.001 at 6 months and 1.84% vs. 1.37% p=0.02 at 12 months, Figure 2). 
In adjusted analyses, patients on TDF were more likely to develop an episode of 
moderate or severe renal dysfunction compared to those on other regimens during the 
first year of ART (Table 2).  
 
Changes in renal function in patients with moderate or severe renal eGFR 
decrease at baseline 
Independent of treatment regimen, individuals with moderate (n=616) or severe (n=110) 
renal dysfunction at baseline showed an improvement in renal function during ART. This 
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included patents who received TDF despite severe renal failure (+30 mL/min after 12 
months, Figure 1). In adjusted analyses, TDF was associated with marginally lower 
renal function at 1 year in individuals with baseline moderate renal dysfunction. On the 
contrary, among patients with available data, TDF use seemed to be associated with a 
higher eGFR during follow-up for those with severe renal dysfunction at ART initiation 
(adjusted difference: +21.7 mL/min, 95% CI: 4.33-39.10 at 1 year; Table 2). Finally, the 
odds of progression from moderate to severe dysfunction were not increased for 
patients starting a TDF-containing ART regimen (aOR 1.11, 95% CI: 0.46, 2.70) (Table 
2). 
 
Mortality 
Over a total follow-up of 111,972 person-years, 2,405 (6.2%) deaths in the TDF group 
and 1,472 (6.3%) in the non-TDF patients were documented. 27.4% and 20.7% of 
patients were LTFU in each group, respectively. Overall, the degree of renal dysfunction 
at ART initiation predicted mortality. For instance, patients with severe renal dysfunction 
at baseline were twice as likely to die during follow-up as those with a normal renal 
function (Table 3). In adjusted analyses stratified by baseline renal function, individuals 
who started a TDF-containing regimen with some degree of renal dysfunction were not 
more likely to die during follow-up compared to those on other treatment regimens 
(Table 2). Notably, there was no detectable difference in mortality between patients on 
TDF and those not on TDF starting ART with moderate (a-sHR: 0.79, 95% CI 0.58, 
1.07) or severe (a-sHR 0.89, 95% CI 0.52, 1.52) eGFR decrease. Other important risk 
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factors for death were male sex, advanced clinical stage of disease, low CD4 cell 
counts and anemia (Table 3).  
 
Sensitivity analyses 
(1) When the analyses were repeated using the MDRD and Cockcroft-Gault equations 
to measure eGFR, we found similar results for all the baseline renal eGFR  categories 
(Web-Tables 1A and 1B). Independently of the formula used, mortality and eGFR 
decrease during follow-up of patients on TDF despite moderate or severe baseline 
eGFR decrease were not higher compared to the outcomes in patients on other 
regimens. (2) Of the patients in the non-TDF group, 1,787 patients (7.6%) initiated ABC. 
Excluding these patients from our analyses did not alter our results significantly (Web-
Table 2). 
 
DISCUSSION 
In this large observational cohort of HIV-1 infected adults in Zambia, TDF did not have a 
significant impact on renal function changes or mortality in patients initiating ART with 
moderate or severe renal dysfunction. Among individuals with no or mild eGFR 
decrease at baseline, those on TDF were more likely to experience an episode of 
moderate or severe renal dysfunction within the first 12 months of ART compared to 
patients on other regimens; however, the overall occurrence of this outcome was rare. 
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Fifteen percent of the patients included in our study had some degree of renal 
dysfunction at ART initiation. This is lower than the proportion reported in other studies 
from sub-Saharan Africa [12, 13]. These differences might have been driven by the 
degree of immunosuppression at ART start, which was less advanced in our study 
compared with the two other reports. Recent improvements in screening for co-
infections associated with renal dysfunction, the avoidance of nephrotoxic drugs, as well 
as the change in CD4 threshold for ART initiation are additional factors that could 
explain this finding. The use of TDF is not recommended for patients with moderate or 
severe eGFR decrease according to most international guidelines. The Zambian 
national guidelines state that patients should initiate a TDF-containing regimen only if 
their creatinine clearance >50mL/min or the absolute serum creatinine ≤ 120 µmol/L. 
Many clinicians use the absolute creatinine value to determine the ART regimen for 
reasons of convenience. As a result, TDF is sometimes prescribed to patients with an 
absolute creatinine ≤ 120 µmol/L but undiagnosed moderate or severe renal eGFR 
decrease, as was the case for 726 patients receiving TDF (1.9%) in our analysis cohort. 
Our study showed that kidney function in individuals with severe baseline eGFR 
decrease improved during the first year of ART, a finding that was even more 
pronounced in those receiving TDF. Although the causes of renal dysfunction in patients 
starting ART in SSA have not been thoroughly investigated, it is assumed that HIV 
associated nephropathy (HIVAN) plays an important role in this setting [26]. As a 
consequence, even ART regimens containing potentially nephrotoxic agents can 
improve renal function in most of the patients with renal insufficiency. Similar to our 
findings, in a large cohort of American HIV-infected veterans, pre-existing renal disease 
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did not appear to worsen the effects of TDF [9]. Of the 3,336 DART trial patients 
included in the analysis of renal outcomes, only 237 (7.0%) had moderate and 7 (0.2%) 
severe renal dysfunction at ART initiation [12, 14]; however,  a detailed analysis of renal 
change by ART regimen was not performed for these patients [14]. In contrast, our 
patients who started a TDF-containing regimen with a moderate eGFR decrease were 
not more likely to develop severe renal dysfunction during ART compared to those on 
other regimens. As expected, mortality increased with worsening baseline eGFR 
decrease  at baseline. However, TDF was not associated with higher mortality in 
patients with moderate or severe renal dysfunction at baseline. Taken together, these 
findings suggest that starting a TDF-containing regimen despite pre-existing renal 
disease may be less harmful than previously thought.  
 
In our study, patients who started ART with normal kidney function seemed to 
experience a slow decline of renal function during the first year, irrespective of ART 
regimen. It has been shown that even though ART seems to slow decline in creatinine 
clearance, a degree of renal function loss appears inevitable, even with durable viral 
suppression [27]. Therefore, ART may only improve kidney function if it is HIV or 
hepatitis B related. In line with recent publications from high-income countries which 
linked TDF with acute and chronic kidney dysfunction [8-10, 14], individuals on TDF in 
our analysis experienced more pronounced reductions in renal function compared to 
those on non-TDF regimens. Furthermore, we observed a two-fold increase in incident 
moderate or severe eGFR decreases in the TDF group. However, the numbers 
remained small, with less than 1% of patients experiencing an episode of severe renal 
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dysfunction (eGFR<30ml/min) 6 or 12 months after ART start. Our findings show that 
the overall impact of TDF on renal outcomes in patients with normal baseline renal 
function is small. Considering the low magnitude or even the absence of this association 
in many previous reports [27, 28] and given its many advantages, poor access to renal 
function monitoring may not be a good justification for withholding TDF in first-line ART. 
 
To our knowledge, this is the largest study assessing the association between TDF and 
renal dysfunction in SSA to date. We provide evidence on the safety of TDF-containing 
regimens in a non-selected population with highly prevalent kidney dysfunction. 
Whereas many studies have examined renal safety of TDF in patients with normal 
baseline renal function, ours provides a detailed description of renal outcomes and 
mortality in patients having received TDF despite pre-existing eGFR decrease. Our 
main limitation was the significant proportion of patients who did not have a follow-up 
creatinine measurement (24.1%). Although we cannot exclude the non-random 
selection of patients who had one or several measurements performed, it is important to 
note that a significant proportion of individuals on TDF were also missing creatinine 
measurements, which reflects the situation of most ART programs in southern Africa. 
Although it is common practice to report renal outcomes as chronic kidney disease 
(CKD), defined as two eGFR measurements below 60 ml/min at least three months 
apart, such diagnoses may be difficult in resource-constrained settings such as Zambia, 
where follow-up testing is not always routinely performed. For this reason, we were 
unable to further distinguish between acute and chronic renal conditions. As single drug 
substitutions were not considered in our analyses, a fraction of the patients who 
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developed renal dysfunction on TDF might have been switched to a non-TDF-containing 
regimen, which might have had an impact on our mortality and severe eGFR decrease 
estimates. Some level of confounding by treatment allocation was also possible, as the 
patients included in this study were not randomized to receive either TDF or non-TDF 
regimens. Therefore, we adjusted our analyses for differences in baseline demographic 
and clinical characteristics. Finally, we could not evaluate long-term renal outcomes, 
and, as creatinine was the only routine measurement of renal function performed in this 
cohort, we could not assess the mechanisms of renal disease such as proximal 
tubulopathy, which has been associated with the use of TDF [29].  
 
In summary, in our analysis of a large observational cohort in Zambia, we show that 
patients receiving TDF-containing ART, despite pre-existing renal disease, did not 
experience worse renal outcomes or increased mortality compared to those taking other 
regimens. Baseline screening of renal dysfunction should be encouraged, as dose 
adjustment of several antiretroviral agents is recommended in case of eGFR decrease. 
However, our data support the view that, poor availability of renal function screening 
should not stop the prescription of TDF-containing ART, considering its numerous 
advantages over other combinations. Studies monitoring and evaluating the long term 
effect of TDF in HIV-infected population in SSA are urgently needed. 
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Table 1: Baseline Characteristics of study population by ART regimen 
   With TDF Without TDF p-value 
   N=38,716 (62%) N=23,514 (38%)  
Female (%)  21,891 (56.5) 16,542 (70.4) <0.001 
Median age in years (IQR)  34 (29-40) 32 (27-38) <0.001 
WHO stage III/IV (%)  22,989 (60.2) 11,218 (48.4) <0.001 
Median BMI in kg/m2 (IQR)  19.7 (17.8-22.1) 20.8 (18.5-22.6) <0.001 
Median CD4 cells/μL (IQR)  151 (82-223) 172 (98-251) <0.001 
    missing (%)  2,333 (6.0) 1,858 (7.9)  
Anemia (%)    <0.001 
    None  10,050 (27.9) 5,650 (26.5)  
    Mild  13,291 (36.8) 8,486 (39.8)  
    Moderate  9,709 (26.9) 5,429 (25.5)  
    Severe  3,034 (8.4) 1,760 (8.3)  
    missing (%)  2,632 (6.8) 2,189 (9.3)  
eGFR decrease (%)    <0.001 
    None  32,247 (83.3) 20,621(87.7)  
    Mild  5,741 (14.8) 1,967 (8.4)  
    Moderate  616 (1.6) 676 (2.9)  
    Severe  110 (0.3) 246 (1.1)  
Calendar year of ART start (%)    <0.001 
    2007  3,204 (8.28) 10,842 (46.1)  
    2008  10,155 (26.2) 4,589 (19.5)  
    2009  12,319 (31.8) 4,594 (19.5)  
    2010 12,110 (31.3) 3,297 (14.0)  
    2011 928 (2.4) 192 (0.9)  
EFV-based ART (%)  23,367 (60.4) 3,913 (16.6) <0.001 
TDF: tenofovir; WHO: World Health Organization; BMI: body mass index; ART: antiretroviral therapy; 
EFV: efavirenz
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Table 2: Comparison of renal outcomes and mortality between patients starting ART with and without TDF using 
CKD EPI (Reference group: patients not on TDF) 
Baseline eGFR 
decrease  
Difference in eGFR                                     
(ml/min) 
 Progression to renal dysfunction  Mortality 
 At 6 months          (95% 
CI) 
At 12 months        (95% 
CI) 
 Severe                 OR 
(95% CI) 
Moderate/severe         
OR (95% CI) 
 sHR (95% CI) 
None -8.64 (-9.40, -7.88) -9.93 (-10.7, -9.14)  3.09 (1.85,5.17) 3.11 (2.52, 3.87)  1.22 (1.13, 1.31) 
Mild -4.55 (-6.42, -2.68) -6.81 (-9.01, -4.61)  5.27 (1.19, 23.2) 2.43 (1.80, 3.28)  0.82 (0.68, 0.98) 
Moderate -6.10 (-11.0, -1.23) -5.37 (-10.9, 0.14)  1.11 (0.46, 2.70) N/A  0.79 (0.58, 1.07) 
Severe 19.3 (2.29, 36.20) 21.7 (4.33, 39.10)  N/A N/A  0.89 (0.52, 1.52) 
TDF: tenofovir; eGFR: estimated glomerular filtration rate; OR: odds ratio; sHR: sub-hazard ration; 95% CI: 95% confidence interval 
All analyses are adjusted for age, sex, calendar year, baseline WHO stage, CD4 cell count and anemia 
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Table 3: Risk factors of mortality 
 
TDF: tenofovir; WHO: World Health Organization; ART: antiretroviral therapy; sHR: sub-hazard ratio; 95% 
CI: 95% confidence interval 
 
 
 
 
Factors Crude SHR 
(95% CI) 
p-value Adjusted SHR 
(95% CI) 
p-value 
TDF 
    No 
    Yes 
Baseline eGFR decrease  
    None 
    Mild 
    Moderate 
    Severe 
 
1 
1.13 (1.06, 1.21) 
 
1 
1.19 (1.09, 1.31) 
2.52 (2.16, 2.94) 
3.77 (2.96, 4.80) 
<0.001 
 
<0.001 
 
 
 
1 
1.14 (1.05, 1.23) 
 
1 
1.24 (1.12, 1.37) 
1.80 (1.53, 2.13) 
2.00 (1.52, 2.63) 
0.001 
 
<0.001 
 
 
Baseline CD4 count (cells/μL) 
    <50 
    50-199 
    >199 
 
1 
0.46 (0.42, 0.51) 
0.23 (0.20, 0.26) 
<0.001 
 
 
 
1 
0.60 (0.56, 0.65) 
0.42 (0.38, 0.47) 
<0.001 
 
 
Anemia 
    None    
    Mild  
    Moderate 
    Severe 
 
1 
2.06(1.78, 2.39) 
3.82 (3.32, 4.40) 
5.93 (1.78, 2.39) 
<0.001 
 
 
 
1 
1.63 (1.45, 1.83) 
2.70 (2.41, 3.03) 
3.88 (3.40, 4.43) 
<0.001 
 
 
Age (years) 1.01 (1.00, 1.01) <0.001 1.01 (1.01, 1.01) <0.001 
Sex    
    Male 
    Female 
 
1 
0.81 (0.75, 0.88) 
<0.001 
 
 
 
1 
0.77 (0.72, 0.83) 
<0.001 
 
 
WHO Stage 
    Stage I or II 
    Stage III 
    Stage IV 
 
1 
2.34 (2.13, 2.58) 
2.56 (2.21, 2.97) 
<0.001 
 
 
 
1 
1.77 (1.62, 1.93) 
2.12 (1.86, 2.41) 
<0.001 
 
 
Calendar year at ART start 
    2007     
    2008 
    2009      
    2010 
 
1 
0.90 (0.80, 1.02) 
0.76 (0.67, 0.85) 
0.30 (0.26, 0.34) 
<0.001 
 
 
 
 
 
1 
0.94 (0.86, 1.02) 
0.71 (0.64, 0.78) 
0.49 (0.43, 0.55) 
<0.001 
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Figure Legends  
Figure 1: Crude change in renal function during ART, by baseline renal function 
and treatment group 
 
 
 
Figure 2. Proportion of patients with no or mild renal dysfunction at baseline 
developing a moderate or severe eGFR decrease on ART 
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